Replies to post #1806 on EOM Pharmaceutical Holdings Inc. (IMUC)

[kris_kade]

FWIW, just scanned the 3Q filings of the top few Institutional holders and none of them have sold out...good sign...

I plan to add if the price dips to 2 tomorrow..PII results are not too far off..

[surf1944]

6:01AM ImmunoCellular Therapeutics provides update on recent 2012 achievements and anticipated milestones; Phase IIb randomized, placebo-controlled, double-blind clinical trial of ICT-107 is progressing well (IMUC) 1.79 : Co's Phase IIb randomized, placebo-controlled, double-blind clinical trial of ICT-107, a dendritic cell vaccine targeting glioblastoma antigens and cancer stem cells, is progressing well. In early 2013, co anticipates that the Data Safety Monitoring Committee will conduct an event-driven interim safety analysis, and that final results will be available in late 2013. Co is on track to file an Investigational New Drug (IND) application for ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells at the end of 2012. Co is planning to initiate a 20-patient, investigator-sponsored Phase I trial of ICT-121, a dendritic cell vaccine targeting CD133, in patients with recurrent glioblastoma, also before the end of 2012. On Nov 17, co will report at the seventeenth annual meeting of the Society for Neuro-Oncology on the "Identification of immunogenic epitopes from CD133 and their potential for use to immunologically target glioblastoma cancer stem cells." Preclinical data supporting the ICT-121 clinical trial, which targets cancer stem cells in patients with recurrent glioblastoma, will be reported. Co is also making progress in recruiting a permanent CEO.